A systemic review and meta-analysis on the efficacy and safety of ferumoxytol for anemia in chronic kidney disease patients

Qianwei Zuo,a Taizhong Wang,a Lirong Zhu,b Xiao Li,b and Qi Luoc

aDepartment of Nephrology, People’s Hospital of Qijiang Distract, Chongqing, P.R. China; bDepartment of Nursing, People’s Hospital of Qijiang Distract, Chongqing, P.R. China; cDepartment of Hematology, People’s Hospital of Qijiang Distract, Chongqing, P.R. China

ABSTRACT

Purpose: To evaluate the efficacy of ferumoxytol, relative to conventional iron supplement formulations, on hemoglobin levels, ferritin level, and adverse event incidence in chronic kidney disease patients.

Methods: We performed a systematic search of six academic databases (EMBASE, CENTRAL, Scopus, PubMed, Web of sciences, and MEDLINE), adhering to PRISMA guidelines. We performed a meta-analysis on relevant studies to evaluate the overall influence of ferumoxytol, relative to conventional iron supplement formulations, on hemoglobin levels, ferritin level, and treatment related treatment emergent adverse events (TEAEs) incidence in chronic kidney disease patients.

Results: Seven eligible studies were identified from a total of 1397 studies. These studies contained data on 3315 participants with chronic kidney disease (mean age: 59.2 ± 4.6 years). A meta-analysis revealed that ferumoxytol administration had positive effects on hemoglobin levels (Hedge’s g statistic: 0.51) and ferritin level (0.88), transferrin saturation (0.39). Besides, we also report reduced incidence of treatment related TEAEs (~0.24) for patients consuming ferumoxytol as compared conventional iron supplement formulations.

Conclusions: This meta-analysis provides preliminary evidence that ferumoxytol use exerts beneficial effects on the overall hematological outcomes in patients with chronic kidney disease. This study also reports improved treatment related safety profile for ferumoxytol when compared with conventional iron formulations. The findings from this study can have direct implications in forming best practice guidelines for managing anemia in patients with chronic kidney disease.

Introduction

Chronic kidney disease is one of the most common renal disorders worldwide [1]. According to the National Kidney Foundation, it is characterized as a pathological condition where glomerular filtration rate drops below ≤ 60 mL/min/1.73 m² [2]. Epidemiological studies have widely reported high prevalence rates of around 10–13% for chronic kidney disease amongst the general population [1,3]. Moreover, the World Health Organization notes that almost 1.1 million deaths occur worldwide every year due to chronic kidney disease [4].

Researchers have linked the presence of anemia in chronic kidney disease with worse prognostic outcomes in terms of mortality and long-term quality of life [5,6]. Erythrocytes are produced through erythropoiesis, a process typically reliant on sufficient levels of a glycoprotein-cytokine such as kidney-produced erythropoietin [7]. However, the extensive damage to nephrotic structures caused by chronic kidney disease, especially within the cortex and medulla, hinders erythropoietin manufacturing [8] and subsequent red blood cell production [9]. In addition, elevated hepcidin levels due to nephrotic inflammation can also instigate anemia by disrupting iron transport and metabolism, as well as by inhibiting erythropoiesis stimulators [10,11]. Finally, increased blood loss due to hemodialysis, increased uremic-inhibitor levels, and reduced erythrocyte lifespan have all been identified as additional factors that cause or aggravate anemia [12–14].

Currently, anemia is managed in chronic kidney disease patients using semi-synthetic poly-glucose sorbitol carboxymethyl ether shell-coated super-paramagnetic iron-oxide nanoparticles such as ferumoxytol [15,16]. The carbohydrate shell helps to isolate the super-paramagnetic iron-oxide nanoparticle from blood plasma, which facilitates particle uptake by reticuloendothelial
system macrophages [15]. In addition, ferumoxytol has been reported to contain the lowest concentrations of ultra-filtrable free iron and dialyzable free iron [16,17]. Ferumoxytol is also popular due to its ability to maintain concentration levels during hemodialysis [18]. That said, a consensus on the efficacy of ferumoxytol compared to other iron supplement formulations for managing anemia in chronic kidney disease is still lacking.

A few randomized controlled trials have attempted to evaluate the efficacy of ferumoxytol compared to other iron supplements, such as iron sucrose, for managing chronic kidney disease. Some studies have reported that oral [19] and intravenous [20] administration of ferumoxytol resulted in reduced adverse events. However, others have noted the opposite [21]. Naturally, no meta-analysis currently exists seeking to evaluate the overall influence of ferumoxytol on chronic kidney disease compared to other iron supplement formulations.

Thus, we herein perform a meta-analysis on the current literature in order to summarize the available data on ferumoxytol use for chronic kidney disease. Our investigation looks at hemoglobin levels, ferritin level, transferrin saturation, and treatment related Treatment Emergent Adverse Events (TEAEs) incidence in chronic kidney disease patients administered ferumoxytol compared to those in patients taking conventional iron supplement formulations. Our findings will hopefully raise clinical awareness among nephrologists concerning how to manage and treat chronic kidney disease and its associated complications.

Methods
This literature review and meta-analysis was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [22].

Data search strategy
Articles published between January 1950 to October 2020 in six academic databases were searched (MEDLINE, CENTRAL, EMBASE, PubMed, Web of sciences, and Scopus). A sample search strategy for the EMBASE database has been provided in Supplementary file. Furthermore, the reference/bibliography sections of included studies were screened manually to identify additional relevant studies. The screening procedure adhered to the following inclusion criteria:

a. Studies must have evaluated hemoglobin levels, ferritin levels (i.e., measures the level of protein ferritin that stores iron in the cells), and treatment related TEAEs incidence in chronic kidney disease patients receiving ferumoxytol.

b. Studies must involve human subjects.

c. Studies must be either randomized controlled trials, quasi-randomized controlled trials, controlled clinical trials, prospective observational trials with control groups, or retrospective trials.

d. Studies must have been published in peer-reviewed academic journals or as part of scientific conference proceedings.

e. Studies must have been published in the English language.

Database and study screening was performed by two independent reviewers. A third independent reviewer served as arbitrator in case of dispute. During screening, we extracted the following information from included studies: author information, descriptive data, country in which the study was conducted, study type, drug administered, dosage regimen follow-up, hemoglobin levels, ferritin level, and adverse event outcomes. For studies where quantitative data was not publically available, we made multiple attempts to contact the study authors to gain access to the relevant data.

Quality assessment
We used Cochrane’s risk of bias assessment tool for randomized controlled trials [23] to assess bias risk in each included individual trial. This tool assesses the possibility of bias in the form of inadequate randomization, selective reporting, concealed allocation, blinding of outcomes, and incomplete data. Methodological quality was appraised by two independent reviewers, with, again, a third reviewer serving as arbitrator if necessary.

Data analysis
Within-group meta-analysis was performed using CMA software (Comprehensive Meta-analysis version 2.0) [24]. The meta-analysis was performed based on a random-effects model [25]. We estimated the weighted effect size (Hedge’s g statistic) and assessed heterogeneity among the studies ($I^2$ statistic). The thresholds used to interpret heterogeneity were as follows: $I^2$ between 0% and 25%: negligible heterogeneity; 25–75%: moderate heterogeneity; $\geq 75%$: substantial heterogeneity [26]. We examined data distribution and analyzed hemoglobin, ferritin levels, and adverse event incidence between study groups receiving ferumoxytol and those
receiving iron supplement formulations. We reported prevalence rates, 95% confidence intervals, levels of significance, and heterogeneity. We also analyzed publication bias using Duval and Tweedy’s trim and fill procedure [27], a method that evaluates whether the overall effect would shift if apparent bias were to be removed. The significance level for this study was determined to be 5%.

**Results**

The systemic literature search performed on six databases identified 1370 candidate studies, while bibliography screening revealed an additional 27 study candidates (Figure 1). After applying inclusion criteria, a total of seven studies remained, all of which were randomized controlled trials [16,19–21,28–30]. The extracted data from these seven studies is found in detail in Table 1.

**Participant information**

The seven studies contained data from a total of 3315 (878 female, 833 male, 1323 not available) patients with chronic kidney disease. Two studies did not provide patient gender information [19,30] A total of 2034 (509 female, 471 male, 886 not available) patients received ferumoxytol, 1281 (369 female, 362 male, 437 not available) received iron supplements or placebo.

Average participant age was $59.2 \pm 4.6$ years. The average age of ferumoxytol-receiving patients was $59 \pm 5.3$ years, while the comparator group average age was $59.4 \pm 4.3$ years.

**Randomized controlled trial quality assessment**

The methodologies of the included randomized controlled trials were assessed for bias risk (Table 2, Figure 2). Overall risk was found to be low, with selective reporting most prominent.

![Figure 1. PRISMA flowchart detailing study identification and inclusion.](image)
| Study                        | Patient status | Type of study                  | Drugs and strength                                      | Sample descriptive | Follow-up | Hemoglobin difference (g/dL) | Ferritin (ng/mL) | TSAT (%)        | Treatment related adverse events (n) |
|-----------------------------|----------------|-------------------------------|---------------------------------------------------------|--------------------|-----------|-----------------------------|-----------------|----------------|----------------------------------|
| Macdougall, Strauss et al. (2019) | HD             | Randomized controlled trial   | Exp: Ferumoxytol IV: 2 × 510 mg Cr: Iron Sucrose IV: 10 × 100 mg | Exp: 196 (82 F, 114 M) Cr: 97 (40 F, 57 M) | Exp: 59.3 ± 14.1 Cr: 57.6 ± 13.6 | 35-days | Exp: 0.5 Cr: 0.4 | –                  | –                  | Exp: 14 Cr: 4 |
| Strauss, Dahl et al. (2016)  | ND             | Randomized controlled trial   | Exp: Ferumoxytol IV: 2 × 510 mg Cr: IV injection or infusion of iron sucrose 200 mg (10 mL) on Day 1 and on 4 other nonconsecutive days over a 14-day period, for a total cumulative dose of 1 g | Exp: 406 Cr: 199 | Exp: 50.1 ± 15.7 Cr: 52.8 ± 16 | 35-days | Exp: 3.3 ± 1.3 Cr: 2.8 ± 0.98 | Exp: 98.3 ± 118.9 Cr: 96.4 ± 185.2 | Exp: 22.9 ± 21.7 Cr: 19.1 ± 14.7 | Exp: 206 Cr: 141 |
|                             | HD             | Slow IV injection or IV drip infusion of 100 mg of iron sucrose on day 1 and at the following 9 consecutive hemodialysis sessions for a total cumulative dose of 1 g | Exp: 80 Cr: 82 | – | Expt: 788.4 ± 427.2 Cr: 618.9 ± 355.4 | Exp: 28.7 ± 8.8 Cr: 27.9 ± 15.8 | Exp: 86 Cr: 161 |
| Macdougall, Strauss et al. (2014) | ND             | Randomized controlled trial   | Exp: Ferumoxytol IV: 2 × 510 mg Cr: Iron Sucrose IV: 10 × 100 mg | Exp: 80 (41 F, 39 M) Cr: 82 (39 F, 43 M) | Exp: 62 ± 15 Cr: 63 ± 15 | 21-days | Exp: 0.8 ± 0.1 Cr: 0.7 ± 0.1 | Exp: 631 Cr: 456 | Exp: 27.5 ± 8 Cr: 25.5 ± 12.7 | Exp: 9 Cr: 25 |
| Lu, Cohen et al. (2010)     | ND             | Randomized controlled trial   | Exp: Ferumoxytol IV: 2 × 510 mg Cr: Oral iron 200 mg/day | Exp: 228 (--) Cr: 76 (--) | – | 35-days | Exp: 0.82 ± 1.24 Cr: 0.16 ± 1.02 | Exp: 1.22 ± 1.25 Cr: 0.52 ± 0.98 | Exp: 10.2 ± 1.13 Cr: 0.46 ± 0.13 | – |
|                             | HD             |                                | Exp: 114 (--) Cr: 116 (--) | – | – | – | – | – | – |
| Provenzano, Schiller et al. (2009) | HD             | Randomized controlled trial   | Exp: Ferumoxytol IV: 2 × 510 mg Cr: Oral iron 200 mg/day | Exp: 114 (57 F, 57 M) Cr: 116 (43 F, 73 M) | Exp: 59.5 ± 14.3 Cr: 60.8 ± 13 | 21-days | – | Exp: 356.6 ± 247.1 Cr: 37.5 ± 106.9 | Exp: 6.2 ± 12.1 Cr: 1.3 ± 8.8 | Exp: 54 Cr: 64 |
| Singh, Patel et al. (2008)  | ND             | Randomized controlled trial   | Exp: Ferumoxytol IV: 2 × 510 mg Cr: Placebo | Exp: 362 (195 F, 167 M) Cr: 360 (195F, 165M) | Exp: 64.2 ± 14.5 Cr: 63 ± 15.1 | 7-days | – | – | – | Exp: 53 Cr: 42 |
| Spinowitz, Kausz et al. (2008) | ND             | Randomized controlled trial   | Exp: Ferumoxytol IV: 2 × 510 mg Cr: Oral iron 200 mg/day | Exp: 228 (134 F, 94 M) Cr: 76 (52 F, 24 M) | Exp: 65.1 ± 14.3 Cr: 63.7 ± 11.1 | 35-days | Exp: 0.82 ± 1.24 Cr: 0.16 ± 1.02 | Exp: 381.7 ± 278.6 Cr: 6.9 ± 60.1 | Exp: 9.8 ± 9.2 Cr: 1.3 ± 6.4 | – |

M: Mean; S.D: Standard deviation; IV: Intravenous; Exp: Experimental group; Ct: Control group; ND: Non-dialysis; HD: Hemodialysis; TSAT: Transferrin saturation.
Publication bias

Duval and Tweedy’s trim and fill method was used to identify missing studies on either side of a funnel plot according to a random effects model. No study was found to be missing on either side of the mean effect. The overall random effects model determined the point estimates and the 95% confidence intervals for the included studies to be $0.24$ ($0.52$ to $0.03$). Application of the trim and fill method did not alter these values (Figure 3).

Meta-analysis report

Hemoglobin level

Five included studies had reported mean differences in hemoglobin levels [19,20,28–30]. A medium positive effect (Hedge’s g statistic: 0.51, Standard error: 0.09, Variance: 0.009, Figure 4) for ferumoxytol was observed (95% CI: $0.33$–$0.69$, Z-value: $5.59$, $p < 0.01$), with negligible heterogeneity ($I^2$: 9.5%).

Ferritin level

Four included studies evaluated ferritin levels [16,28–30]. A large positive effect (Hedge’s g statistic: 0.88, Standard error: 0.36, Variance: 0.13, Figure 5) for ferumoxytol was observed (95% CI: $0.17$–$1.59$, Z-value: $2.4$, $p = 0.01$), with no heterogeneity ($I^2$: 0%).

Transferrin saturation

Five included studies evaluated transferrin saturation [16,19,28–30]. A medium positive effect (Hedge’s g statistic: 0.39, Standard error: 0.17, Variance: 0.02, Figure 6) for ferumoxytol was observed (95% CI: $0.05$–$0.73$, Z-value: $2.3$, $p = 0.02$), with no heterogeneity ($I^2$: 0%).

Treatment related TEAEs

Six included studies evaluated treatment related TEAEs [19–21,28–30]. A small negative effect (Hedge’s g statistic: $-0.24$, standard error: 0.14, variance: 0.02 Figure 7) for the iron supplement-receiving patients was
observed (95% C.I: −0.52−0.03, Z-score: −1.69, p = 0.08), with negligible heterogeneity ($I^2$: 24.1%).

**Discussion**

This meta-analysis provides novel evidence regarding the comparative efficacy of ferumoxytol against other conventional iron supplement formulations for managing chronic kidney disease. We observed that ferumoxytol administration was beneficial relative to conventional iron supplement formulations in terms of hemoglobin level management, ferritin level, transferrin saturation and limiting treatment related TEAEs in patients with chronic kidney disease. Managing chronic kidney disease is highly challenging because of its atypical pathophysiological mechanisms, co-existing morbidities, and manifestation [31,32]. Anemia, one of the most common co-morbidities [33], has been associated with poor prognostic outcome in terms of short- and long-term morbidity and mortality for chronic kidney disease [34–36]. Anemia onset in chronic kidney disease patients is primarily caused by reduced erythropoietin levels and disrupted iron metabolism [14]. Studies have also suggested a direct relationship between anemia severity and chronic kidney disease severity [33]. Ferumoxytol use has intensified in recent decades for managing anemia co-existing with chronic kidney disease for a number of reasons [15,16]. First, ferumoxytol reportedly overcomes...
reticuloendothelial system blockage caused by chronic kidney disease, thereby ensuring sufficient iron reserve bioavailability for anemia management [37]. Second, the drug possesses a superior pharmaco-kinetic profile, presenting a higher safety profile and permitting daily dosing regimens [15]. Third, ferumoxytol concentrations...
are maintained even after hemodialysis [18]. Fourth, this compound can enhance hemoglobin levels and ferritin levels relative to conventional iron supplement formulations.

This last point is echoed in our study, where all the included studies reported that ferumoxytol was beneficial relative to conventional iron supplement formulations when it came to mediating hemoglobin levels in chronic kidney disease patients. Provenzano et al. [29], for instance, reported in a phase-III randomized controlled trial that a 510 mg dosage of ferumoxytol increased hemoglobin levels and ferritin levels far more than a 200-mg dosage of oral iron supplementation after 21 and 35 days of administration among 230 chronic kidney disease patients on hemodialysis. The authors also mentioned that ferumoxytol also improved other hematological outcomes such as transferrin saturation, reticulocyte hemoglobin content, and total iron binding capacity. Similarly, Macdougall et al. [28] reported that 1020 mg ferumoxytol in two doses outperformed 1000 mg iron sucrose administered via injection/intravenous infusion. Here, ferumoxytol improved hematological outcomes beginning at 14 days until 35 days after administration. In our present meta-analysis, we confirm these findings and report that ferumoxytol administration resulted in a medium positive overall effect on hemoglobin levels (Hedge’s g statistic: 0.33), and transferrin saturation (Hedge’s g: 0.39) in chronic kidney disease patients. We also reported that ferumoxytol administration resulted in a large positive effect on ferritin level (Hedge’s g: 0.88) in chronic kidney disease patients.

We also attempted to establish whether there were differences in treatment related TEAEs incidence when using ferumoxytol versus other conventional iron supplement formulations. Here, Lu et al., Macdougall et al., Strauss et al., and Provenzano et al. [19,28–30] all reported fewer treatment related TEAEs for ferumoxytol-using patients compared to those given conventional iron supplement formulations. Overall, our meta-analysis reports a decreased treatment related TEAEs effect for ferumoxytol users relative to conventional iron supplement formulation-using chronic kidney disease patients.

This study was hampered by several limitations. First, we were unable to register this meta-analysis in a review repository such as PROSPERO. This may raise some concern regarding the validity of this study [38]. However, we made considerable efforts to register our review with PROSPERO and other such repositories, only to be informed that wait times exceeded 1 year due to the current pandemic crisis. Second, we did not provide a descriptive explanation for the studies study that were excluded. Third, insufficient available data meant that we could not carry out sub-group analyses effectively. Moreover, as we did not observe heterogeneity, we strongly recommend that our results be interpreted with caution and hope that future studies will be able to address these limitations by making more data publicly available.

In conclusion, we herein provide a preliminary summation regarding the comparative efficacy of ferumoxytol versus conventional iron supplement formulations. We note that ferumoxytol elevates hemoglobin levels, transferrin saturation and ferritin levels in patients with chronic kidney disease, compared to conventional iron supplement formulations. Moreover, we report reduced incidence of treatment related TEAEs with ferumoxytol administration.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
The author(s) reported there is no funding associated with the work featured in this article.

Data availability statement
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References
[1] Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. Plos One. 2016;11(7):e0158765.
[2] Johnson RJ, Feehally J, Floege J. Comprehensive clinical nephrology E-Book. Philadelphia, PA: Elsevier Health Sciences; 2014.
[3] Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822.
[4] Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):414–422D.
[5] Robinson BM, Joffe MM, Berns JS, et al. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int. 2005;68(5):2323–2330.
[6] Walters BAJ, Hays RD, Spritzer KL, et al. Health-related quality of life, depressive symptoms, anemia, and malnutrition at hemodialysis initiation. Am J Kidney Dis off J Natl Kidney Found. 2002;40(6):1185–1194.
[7] O’Mara NB. Anemia in patients with chronic kidney disease. Diabetes Spectr. 2008;21:12–19.
[8] Souma T, Suzuki N, Yamamoto M. Renal erythropoietin-producing cells in health and disease. Front Physiol. 2015;6:167.

[9] Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res. 2011;17(20):6373–6380.

[10] Malyszko J, Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res. 2007;30(1):15–30.

[11] van der Weerd NC, Grooteman MPC, Nubé MJ, et al. Hepcidin in chronic kidney disease: not an anaemia management tool, but promising as a cardiovascular biomarker. Neth J Med. 2015;73:108–118.

[12] Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis off J Natl Kidney Found. 2004;44(4):715–719.

[13] Macdougall IC. Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int Suppl. 2001;78:567–572.

[14] Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif. 2004;22(1):112–123.

[15] McCormack PL. Ferumoxytol: in iron deficiency anemia in adults with chronic kidney disease. Drugs. 2012;72(15):2013–2022.

[16] Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. JASN. 2008;19(8):1599–1605.

[17] Balakrishnan VS, Rao M, Kausz AT, Brenner L, et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest. 2009;39(6):489–496.

[18] Landry R, Jacobs PM, Davis R, et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol. 2005;25(4):400–410.

[19] Lu M, Cohen MH, Rieves D, et al. Report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010;85(5):315–319.

[20] Macdougall IC, Strauss WE, Dahl NV, et al. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial. CN. 2019;91(4):237–245.

[21] Singh A, Patel T, Hertel J, et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008;52(5):907–915.

[22] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

[23] Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

[24] Bax L, Yu L-M, Ikeda N, et al. A systematic comparison of software dedicated to Meta-analysis of causal studies. BMC Med Res Methodol. 2007;7:40.

[25] Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137–159.

[26] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statist Med. 2002;21(11):1539–1558.

[27] Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–463.

[28] Macdougall IC, Strauss WE, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. CJASN. 2014;9(4):705–712.

[29] Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. CJASN. 2009;4(2):386–393.

[30] Strauss WE, Dahl NV, Li Z, et al. Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia. BMC Hematol. 2016;16:20.

[31] López-Novoa JM, Martínez-Salgado C, Rodríguez-Peña AB, et al. Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. Pharmacol Ther. 2010;128(1):61–81.

[32] Yang L, Humphreys BD, Bonventre JV. Pathophysiology of acute kidney injury to chronic kidney disease: maladaptive repair. Contrib Nephrol. 2011;174:149–155.

[33] Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631–1634.

[34] Collister D, Rigatto C, Tangri N. Anemia management in chronic kidney disease and dialysis: a narrative review. Curr Opin Nephrol Hypertens. 2017;26(3):214–218.

[35] Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19(1):121–132.

[36] McCullough PA, Lepor NE. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med. 2005;6(Suppl 3):S4–S12.

[37] Schwenk MH. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy. 2010;30(1):70–79.

[38] Best practice in systematic reviews: the importance of protocols and registration. PLoS Med. 2011;8:e1001009.